Effect of angiotensin II receptor blockers on blood pressure changes at daily monitoring depending on morning or evening reception

Main Article Content

O. L. Rekovets
Yu. M. Sirenko
O. O. Torbas
O. O. Kushnir
G. F. Prymak

Abstract

The aim – to evaluate the effect of angiotensin II receptor blockers olmesartan, azilsartan and telmisartan when administered in the morning or evening hours on blood pressure (BP) indices during daily monitoring in patients with arterial hypertension (AH).
Materials and methods. The study involved 126 patients with mild to moderate hypertension who were selected to compare the effect of angiotensin II receptor blockers – olmesartan, azilsartan and telmisartan – in the morning and evening hours. They were divided into 6 groups: 20 patients taking olmesartan at a dose of 20–40 mg in the morning,
20 patients taking olmesartan at a dose of 20–40 mg in the evening, 21 patients taking azilsartan at a dose of 40–80 mg in the morning, 20 patients taking azilsartan at a dose of 40–80 mg in the evening, 22 patients taking telmisartan at a dose of 40–80 mg in the morning, 23 patients taking telmisartan at a dose of 40–80 mg in the evening. Patients underwent primary examination and repeated one – after 3 months of therapy.
Results and discussion. Evening reception of olmesartan, compared with morning one, led to a more pronounced decrease in diurnal systolic blood pressure (SBT) – (11.09±2.30) vs (4.06±2.25) mm Hg (p<0.01). Changes in diurnal diastolic blood pressure (DBP) were statistically insignificant, although its decrease during evening reception was more significant compared to decrease during morning reception ((8.38±2.58) mm Hg versus (3.38±2.31) mm Hg). Changes in daily blood pressure against reception of azilsartan in the evening and morning hours were statistically significant, but did not differ from each other ((13.06±2.65)/(9.76±1.73) vs. (12.71±1.62)/(7.00±1.50) mm Hg). Reduction of diurnal blood pressure at the background of telmisartan administration was statistically significantly more pronounced in the morning than in the evening intake ((16.48±2.86)/(12.56±2.80) vs. (4.93±1.53)/(5.40±1.89) mm Hg, p<0.01). Thus, morning reception more significantly lowered the average daily blood pressure against the background of taking telmisartan, and the evening reception – against the background of taking olmesartan. Azilsartan equally reduced the blood pressure both at evening and morning admission. The rate of achievement of target BP at daily monitoring against the background of the administration of olmesartan, azilsartan and telmisartan was 71.80; 71.0 and 75.61 %, respectively.
Conclusions. Admission of telmisartan more significantly reduced the average daily blood pressure in morning hours compared to evening hours, olmesartan better lowered the average daily blood pressure when taken in the evening, and the use of azilsartan equally affected the decrease in blood pressure regardless of the time of taking the drug.

Article Details

Keywords:

arterial hypertension, chronotherapy, circadian rhythm, evening reception, morning reception

References

Bartter FC, Delea CS, Baker W. Chronobiology in the diagnosis and treatment of hypertension. Chronobiologia 1976;3(3):199–213. https://doi.org/10.1007/978-1-4684-2847-6_10.

Bowles NP, Thosar SS, Herzig MX, Shea SA. Chronotherapy for Hypertension. Current Hypertension Reports 2018;20:97 https://doi.org/10.1007/s11906-018-0897-4

Hermida R, Ayala D, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010;27(8):1629–1651.

Hermida RC, Ayala DE, Mojo ́n A, Fernández JR. Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial. Diabetologia 2016;59: 255–265.

Hermida RC, Ayala DE, Mojo ́n A, Fernández JR. Prognostic marker of type 2 diabetes and therapeutic target for prevention. Diabetologia 2016;59:244–254.

Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011;22(12):2313–2321.

Hermida RC, Ayala DE, Mojón A, Fernández JR. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am J Hypertens 2010; 23:432–439.

Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of time of day of blood pressure–lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011;34(6):1270–1276.

Hermida RC, Smolensky MH, Ayala DE, Fernández JR, Moyá A, Crespo JJ, Mojón A, Ríos MT, Fabbian F, Portaluppi F. Ambulatory blood pressure monitoring (ABPM) as the reference standard for diagnosis of hypertension and assessment of vascular risk in adults. Chronobiol Int 2015;32:1329–1342.

Judd E, Calhoun D. Management of Hypertension in CKD: Beyond the Guidelines. Adv Chronic Kidney Dis. 2015;22(2):116–122. https://doi.org/10.1053/j.ackd.2014.12.001.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:100–150.

Manfredini R, Fabbian F. A pill at bedtime, and your heart is fine? Bedtime hypertension chronotherapy: an opportune and advantageous inexpensive treatment strategy. Sleep Med Rev 2017;33:1–3.

Orías M, Correa-Rotter R. Chronotherapy in hypertension: a pill at night makes things right? J Am Soc Nephrol 2011;22(12):2152–2155.

Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbai F, Hiremath L, Jamerson K, Kendrick C, Kusek JW, Lash JP, Lea J, Miller III ER, Rostand S, Toto R, Wang X, Wright Jr JT, Appel LJ. A Trial of two strategies to reduce nocturnal blood pressure in african americans with chronic kidney disease. Hypertension. 2013 January;61(1):82–88. https://doi.org/10.1161/HYPERTENSIONAHA.112.200477.

Ramón C. Hermida, Diana E. Ayala, José R. Fernández, Artemio Mojón, Juan J. Crespo, MD, María T. Ríos, Michael H. Smolensky, Bedtime Blood Pressure Chronotherapy Significantly Improves Hypertension Management. Heart Failure Clin. 2017 http://dx.doi.org/10.1016/j.hfc.2017.05.010 1551-7136/17/

Shen Y, Lu X. Clinical study of taking medicine at bedtime for CKD patients to reduce cardiovascular events. Mod Instrum Med Treatment 2014;20:89–91.

Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst. 2000;1(1):18–20.

Smolensky MH, Hermida, RC, Ayala DE, Mojón A, Fernández JR. Bedtime Chronotherapy with Conventional Hypertension Medications to Target Increased Asleep Blood Pressure Results in Markedly Better Chronoprevention of Cardiovascular and Other Risks than Customary On-awakening Therapy. Heart Failure Clin. 2017 http://dx.doi.org/10.1016/j.hfc.2017.05.011

Smolensky MH, Hermida RC, Ayala DE, Portaluppi F. Bedtime hypertension chronotherapy: concepts and patient outcomes. Curr Pharm Des 2015;21(6):773–790. https://doi.org/10.2174/1381612820666141024150542

Staessen J, Fagard R, Thijs L, O'Brien. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350(9080):757–764. https://doi.org/10.1016/s0140-6736(97)05381-6

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl. J Med. 2000;342:145–153. https://doi.org/10.1056/nejm200003093421023

Jatoi NA, Mahmud A, Bennett K, Feely J. Assessment of arterial stiffness in hypertension: comparison of oscillometric (Arteriograph), piezoelectronic (Complior) and tonometric (SphygmoCor) techniques. J Hypertens. 2009;27(11):2186–2191. https://doi.org/10.1097/hjh.0b013e32833057e8

Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham heart study. Circulation. 2010;121(4):505–511. https://doi.org/10.1161/circulationaha.109.886655